White Paper

Objectives And Considerations In Developing An Integrated Summary Of Efficacy (ISE)

Source: Rho

By Ben Vaughn

A new drug application (NDA) covers information about a product from inception through clinical trials. The integrated summary of efficacy (ISE) is a section of the NDA that provides a focused summary of efficacy data primarily from the pivotal phase 3 trials. This article discusses the primary goals and considerations for developing an ISE.

access the White Paper!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)